Laura Lowe Furge
Affiliations: | Chemistry | Kalamazoo College |
Google:
"Laura Furge"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| F Peter Guengerich | grad student | 1993-1998 | Vanderbilt Medical School |
| Stanley Cohen | post-doc | 1998-1999 | Vanderbilt Medical School |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| McCarty KD, Ratliff SA, Furge KA, et al. (2020) . Drug Metabolism and Disposition: the Biological Fate of Chemicals |
| McCarty KD, Furge KA, Furge L. (2020) Tryptophan‐75 is a Potential Gating Residue of Cytochrome P450 2D6 The Faseb Journal. 34: 1-1 |
| Glass SM, Leddy SM, Orwin MC, et al. (2019) Rolapitant is a reversible inhibitor of CYP2D6. Drug Metabolism and Disposition: the Biological Fate of Chemicals |
| Glass SM, Martell CM, Oswalt AK, et al. (2018) CYP2D6 allelic variants *34, *17-2, *17-3, and *53 and a Thr309Ala mutant display altered kinetics and NADPH coupling in metabolism of bufuralol and dextromethorphan and altered susceptibility to inactivation by SCH 66712. Drug Metabolism and Disposition: the Biological Fate of Chemicals |
| Furge LL, Glass SM, Cho C, et al. (2018) Allelic variants of CYP2D6 have altered drug metabolite profile, kinetics, and susceptibility to mechanism-based inactivation Drug Metabolism and Pharmacokinetics. 33 |
| de Waal PW, Sunden KF, Furge LL. (2014) Molecular dynamics of CYP2D6 polymorphisms in the absence and presence of a mechanism-based inactivator reveals changes in local flexibility and dominant substrate access channels. Plos One. 9: e108607 |
| Bolles AK, Fujiwara R, Briggs ED, et al. (2014) Mechanism-based inactivation of human cytochrome P450 3A4 by two piperazine-containing compounds. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 42: 2087-96 |
| Livezey MR, Briggs ED, Bolles AK, et al. (2014) Metoclopramide is metabolized by CYP2D6 and is a reversible inhibitor, but not inactivator, of CYP2D6. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 44: 309-19 |
| Livezey M, Nagy LD, Diffenderfer LE, et al. (2012) Molecular analysis and modeling of inactivation of human CYP2D6 by four mechanism based inactivators. Drug Metabolism Letters. 6: 7-14 |
| Furge LL, Guengerich FP. (2012) Cytochrome P450 enzymes in drug metabolism and chemical toxicology: An introduction. Biochemistry and Molecular Biology Education : a Bimonthly Publication of the International Union of Biochemistry and Molecular Biology. 34: 66-74 |